{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T06:36:16Z","timestamp":1725345376371},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,1]]},"DOI":"10.7759\/cureus.38401","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T18:46:18Z","timestamp":1682966778000},"source":"Crossref","is-referenced-by-count":2,"title":["Fulminant Clostridioides difficile Colitis With SARS-CoV-2 Infection"],"prefix":"10.7759","author":[{"given":"Sanchit","family":"Duhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijeta","family":"Keisham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahlaa","family":"Salim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1756284819847651","article-title":"Management of Clostridioides difficile colitis: insights for the gastroenterologist","volume":"12","author":"Saha S","year":"2019","unstructured":"Saha S, Khanna S. Management of Clostridioides difficile colitis: insights for the gastroenterologist. Therap Adv Gastroenterol. 2019, 12:10.1177\/1756284819847651","journal-title":"Therap Adv Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab236","article-title":"Trends in antibiotic use in United States hospitals during the coronavirus disease 2019 pandemic","volume":"8","author":"Rose AN","year":"2021","unstructured":"Rose AN, Baggs J, Wolford H, et al.. Trends in antibiotic use in United States hospitals during the coronavirus disease 2019 pandemic. Open Forum Infect Dis. 2021, 8:10.1093\/ofid\/ofab236","journal-title":"Open Forum Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.4.525","article-title":"Clostridium difficile-associated diarrhea: a review","volume":"161","author":"Mylonakis E","year":"2001","unstructured":"Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associated diarrhea: a review. Arch Intern Med. 2001, 161:525-33. 10.1001\/archinte.161.4.525","journal-title":"Arch Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.05.048","article-title":"Alterations in gut microbiota of patients with COVID-19 during time of hospitalization","volume":"159","author":"Zuo T","year":"2020","unstructured":"Zuo T, Zhang F, Lui GC, et al.. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020, 159:944-55. 10.1053\/j.gastro.2020.05.048","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.06.003","article-title":"Prevalence and mortality of COVID-19 patients with gastrointestinal symptoms: a systematic review and meta-analysis","volume":"95","author":"Tariq R","year":"2020","unstructured":"Tariq R, Saha S, Furqan F, Hassett L, Pardi D, Khanna S. Prevalence and mortality of COVID-19 patients with gastrointestinal symptoms: a systematic review and meta-analysis. Mayo Clin Proc. 2020, 95:1632-48. 10.1016\/j.mayocp.2020.06.003","journal-title":"Mayo Clin Proc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2020-0275","article-title":"The interplay of SARS-CoV-2 and Clostridioides difficile infection","volume":"16","author":"Khanna S","year":"2021","unstructured":"Khanna S, Kraft CS. The interplay of SARS-CoV-2 and Clostridioides difficile infection. Future Microbiol. 2021, 16:439-43. 10.2217\/fmb-2020-0275","journal-title":"Future Microbiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2021-0145","article-title":"Clostridioides difficile co-infection in patients with COVID-19","volume":"17","author":"Maslennikov R","year":"2022","unstructured":"Maslennikov R, Ivashkin V, Ufimtseva A, Poluektova E, Ulyanin A. Clostridioides difficile co-infection in patients with COVID-19. Future Microbiol. 2022, 17:653-63. 10.2217\/fmb-2021-0145","journal-title":"Future Microbiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3201\/eid2609.202126","article-title":"Clostridioides difficile in COVID-19 patients, Detroit, Michigan, USA, March-April 2020","volume":"26","author":"Sandhu A","year":"2020","unstructured":"Sandhu A, Tillotson G, Polistico J, et al.. Clostridioides difficile in COVID-19 patients, Detroit, Michigan, USA, March-April 2020. Emerg Infect Dis. 2020, 26:2272-4. 10.3201\/eid2609.202126","journal-title":"Emerg Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.12890\/2021_002771","article-title":"COVID-19 and fulminant Clostridium difficile colitis co-infection","volume":"8","author":"Sheikh AA","year":"2021","unstructured":"Sheikh AA, Sheikh AB, Shah I, Khair AH, Javed N, Shekhar R. COVID-19 and fulminant Clostridium difficile colitis co-infection. Eur J Case Rep Intern Med. 2021, 8:10.12890\/2021_002771","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2015.05.005","article-title":"Application of the ATLAS score for evaluating the severity of Clostridium difficile infection in teaching hospitals in Mexico","volume":"19","author":"Hern\u00e1ndez-Garc\u00eda R","year":"2015","unstructured":"Hern\u00e1ndez-Garc\u00eda R, Garza-Gonz\u00e1lez E, Miller M, Arteaga-Muller G, Galv\u00e1n-de los Santos AM, Camacho-Ortiz A. Application of the ATLAS score for evaluating the severity of Clostridium difficile infection in teaching hospitals in Mexico. Braz J Infect Dis. 2015, 19:399-402. 10.1016\/j.bjid.2015.05.005","journal-title":"Braz J Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.775063","article-title":"How does COVID-19 pandemic impact on incidence of Clostridioides difficile infection and exacerbation of its gastrointestinal symptoms?","volume":"8","author":"Azimirad M","year":"2021","unstructured":"Azimirad M, Noori M, Raeisi H, et al.. How does COVID-19 pandemic impact on incidence of Clostridioides difficile infection and exacerbation of its gastrointestinal symptoms?. Front Med (Lausanne). 2021, 8:10.3389\/fmed.2021.775063","journal-title":"Front Med (Lausanne)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-04935-6","article-title":"Functional and cognitive status in Clostridium difficile infection in the hospitalized elderly: a retrospective study of two sites","volume":"34","author":"Fernandez-Cotarelo MJ","year":"2019","unstructured":"Fernandez-Cotarelo MJ, Nagy-Agren SE, Smolkin ME, Jimenez-Diez-Canseco L, Perez-Pomata MT, Shenal BV, Warren CA. Functional and cognitive status in Clostridium difficile infection in the hospitalized elderly: a retrospective study of two sites. J Gen Intern Med. 2019, 34:1392-3. 10.1007\/s11606-019-04935-6","journal-title":"J Gen Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2021.102502","article-title":"Fecal microbiota transplantation as therapy for recurrent Clostridioides difficile infection is associated with amelioration of delirium and accompanied by changes in fecal microbiota and the metabolome","volume":"73","author":"Gotoh K","year":"2022","unstructured":"Gotoh K, Sakaguchi Y, Kato H, et al.. Fecal microbiota transplantation as therapy for recurrent Clostridioides difficile infection is associated with amelioration of delirium and accompanied by changes in fecal microbiota and the metabolome. Anaerobe. 2022, 73:10.1016\/j.anaerobe.2021.102502","journal-title":"Anaerobe"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021001","article-title":"The role of fecal microbiota transplantation in the treatment of neurodegenerative diseases: a review","volume":"24","author":"Matheson JT","year":"2023","unstructured":"Matheson JT, Holsinger RM. The role of fecal microbiota transplantation in the treatment of neurodegenerative diseases: a review. Int J Mol Sci. 2023, 24:10.3390\/ijms24021001","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2438","article-title":"Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19","volume":"40","author":"Jorgensen SC","year":"2020","unstructured":"Jorgensen SC, Tse CL, Burry L, Dresser LD. Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy. 2020, 40:843-56. 10.1002\/phar.2438","journal-title":"Pharmacotherapy"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/143112-fulminant-clostridioides-difficile-colitis-with-sars-cov-2-infection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:57:58Z","timestamp":1707508678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/143112-fulminant-clostridioides-difficile-colitis-with-sars-cov-2-infection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.38401","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}